Department of Medicine and Surgery, ASST Settelaghi University Teaching Hospital, University of Insubria School of Medicine, Via Guicciardini, 9, 21100, Varese, Italy.
Department of Cardiovascular Surgery, Poliambulanza Foundation, Brescia, Italy.
World J Surg. 2020 Jun;44(6):2010-2019. doi: 10.1007/s00268-020-05415-3.
We present a comparison of renal function outcomes during HTAR with the use of a new hybrid vascular graft (GHVG) or standard graft.
It is a multicenter, retrospective, observational study. Between January 2015 and March 2019, 36 patients were treated with HTAR. We compared HTAR performed with the use of the GHVG and with the use of standard bypass graft. Primary outcome measures were hospital mortality, acute kidney injury (AKI) at 30 days and GHVG patency.
Mean GHVG ischemia time was significantly lower for both renal arteries (right: GHVG, 4 ± 2 vs. standard graft, 15 ± 7 min; 95% CI 2.23-6.69, P < 0.001; left: GHVG, 3 ± 2 vs. standard graft, 13 ± 7 min; 95% CI 2.44-5.03, P < 0.001). Hospital mortality was 17% (6/36); while mortality did not differ between the two groups, postoperative acute kidney injury rate was 30.5% (11/36 patients) and was more common in the standard graft group (7% vs. 29%; OR 3.2, P = 0.074). Estimated primary patency was 92% ± 2 (95% CI 79.5-97%) at 36 months and was not different between the two groups (GHVG 94% ± 6 vs. standard graft 91% ± 6; log-rank χ = 0.260, P = 0.610).
In our experience of HTAR, ischemia time was significantly shorter and postoperative AKI occurrence was lower with GHVG if compared to standard graft bypass, with satisfactory midterm patency rate comparable to that of standard graft bypass.
我们比较了使用新型杂交血管移植物(GHVG)与标准移植物进行 HTAR 的肾功能结果。
这是一项多中心、回顾性、观察性研究。2015 年 1 月至 2019 年 3 月,36 例患者接受 HTAR 治疗。我们比较了使用 GHVG 和标准旁路移植物进行 HTAR 的结果。主要观察指标为住院死亡率、术后 30 天急性肾损伤(AKI)和 GHVG 通畅率。
双侧肾动脉的 GHVG 缺血时间均明显低于标准移植物(右侧:GHVG 为 4±2 分钟,标准移植物为 15±7 分钟;95%CI 2.23-6.69,P<0.001;左侧:GHVG 为 3±2 分钟,标准移植物为 13±7 分钟;95%CI 2.44-5.03,P<0.001)。住院死亡率为 17%(6/36);两组死亡率无差异,但标准移植物组术后急性肾损伤发生率为 30.5%(11/36 例),高于 GHVG 组(7%比 29%;OR 3.2,P=0.074)。36 个月时估计的主要通畅率为 92%±2(95%CI 79.5-97%),两组间无差异(GHVG 为 94%±6,标准移植物为 91%±6;对数秩 χ²=0.260,P=0.610)。
在我们的 HTAR 经验中,与标准移植物旁路相比,使用 GHVG 可显著缩短缺血时间,降低术后 AKI 发生率,中期通畅率与标准移植物旁路相当。